DOCSLIB.ORG

Table 4. V. Cholerae Flexgene ORF Collection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Table 4. V. cholerae FLEXGene ORF collection Reference Clone protein PlasmID clone GenBank Locus tag Symbol accession identifier FLEX clone name accession Product name VC0001 NP_062585 VcCD00019918 FLH200476.01F DQ772770 hypothetical protein VC0002 mioC NP_062586 VcCD00019938 FLH200506.01F DQ772771 mioC protein VC0003 thdF NP_062587 VcCD00019958 FLH200531.01F DQ772772 thiophene and furan oxidation protein ThdF VC0004 yidC NP_062588 VcCD00019970 FLH200545.01F DQ772773 inner membrane protein, 60 kDa VC0005 NP_062589 VcCD00061243 FLH236482.01F DQ899316 conserved hypothetical protein VC0006 rnpA NP_062590 VcCD00025697 FLH214799.01F DQ772774 ribonuclease P protein component VC0007 rpmH NP_062591 VcCD00061229 FLH236450.01F DQ899317 ribosomal protein L34 VC0008 NP_062592 VcCD00019917 FLH200475.01F DQ772775 amino acid ABC transporter, ATP-binding protein VC0009 NP_062593 VcCD00019966 FLH200540.01F DQ772776 amino acid ABC transproter, permease protein VC0010 NP_062594 VcCD00019152 FLH199275.01F DQ772777 amino acid ABC transporter, periplasmic amino acid-binding portion VC0011 NP_062595 VcCD00019151 FLH199274.01F DQ772778 hypothetical protein VC0012 dnaA NP_062596 VcCD00017363 FLH174286.01F DQ772779 chromosomal DNA replication initiator DnaA VC0013 dnaN NP_062597 VcCD00017316 FLH174063.01F DQ772780 DNA polymerase III, beta chain VC0014 recF NP_062598 VcCD00019182 FLH199319.01F DQ772781 recF protein VC0015 gyrB NP_062599 VcCD00025458 FLH174642.01F DQ772782 DNA gyrase, subunit B VC0016 NP_229675 VcCD00019198 FLH199346.01F DQ772783 hypothetical protein VC0017 NP_229676 VcCD00019145 FLH199266.01F DQ772784 hypothetical protein VC0018 ibpA NP_229677 VcCD00061122 FLH234790.01F DQ899318 16 kDa heat shock protein A VC0019 avtA NP_229678 VcCD00025656 FLH214606.01F DQ772785 valine-pyruvate aminotransferase VC0020 glyS NP_229679 VcCD00017428 FLH174578.01F DQ772786 glycyl-tRNA synthetase, beta chain VC0021 glyQ NP_229680 VcCD00019175 FLH199311.01F DQ772787 glycyl-tRNA synthetase, alpha chain VC0022 NP_229681 VcCD00019146 FLH199267.01F DQ772788 conserved hypothetical protein VC0023 NP_229682 VcCD00019167 FLH199296.01F DQ772789 NADH dehydrogenase subunit II-related protein VC0024 NP_229683 VcCD00019165 FLH199294.01F DQ772790 conserved hypothetical protein VC0025 NP_229684 VcCD00019163 FLH199292.01F DQ772791 hypothetical protein VC0026 NP_229685 VcCD00019170 FLH199305.01F DQ772792 zinc-binding alcohol dehydrogenase VC0027 ilvA NP_229686 VcCD00025657 FLH214610.01F DQ772793 threonine dehydratase VC0028 ilvD NP_229687 VcCD00025658 FLH214615.01F DQ772794 dihydroxy-acid dehydratase VC0029 ilvE NP_229688 VcCD00019168 FLH199297.01F DQ772795 branched-chain amino acid amiotransferase VC0030 ilvM NP_229689 VcCD00061095 FLH234718.01F DQ899319 acetolactate synthase II, small subunit VC0031 ilvG NP_229690 VcCD00019197 FLH199345.01F DQ772796 acetolactate synthase II, large subunit VC0032 NP_229691 VcCD00019193 FLH199339.01F DQ772797 ComM-related protein VC0033 NP_229692 VcCD00025652 FLH214586.01F DQ772798 conserved hypothetical protein VC0034 tpcG NP_229693 VcCD00019144 FLH199265.01F DQ772799 thiol:disulfide interchange protein VC0035 NP_229694 VcCD00019181 FLH199317.01F DQ772800 conserved hypothetical protein VC0036 NP_229695 VcCD00025587 FLH199335.01F DQ772801 FixG-related protein VC0037 NP_229696 VcCD00025777 FLH218584.01F DQ772802 conserved hypothetical protein VC0038 NP_229697 VcCD00061076 FLH234670.01F DQ899320 hypothetical protein VC0039 NP_229698 VcCD00019160 FLH199287.01F DQ772803 SpoOM-related protein VC0040 NP_229699 VcCD00025571 FLH199174.01F DQ772804 hemolysin, putative VC0041 NP_229700 VcCD00025573 FLH199178.01F DQ772805 conserved hypothetical protein VC0042 trkH-1 NP_229701 VcCD00019131 FLH199245.01F DQ772806 potassium uptake protein TrkH VC0043 trkA NP_229702 VcCD00019128 FLH199238.01F DQ772807 potassium uptake protein TrkA VC0044 sun NP_229703 VcCD00019125 FLH199232.01F DQ772808 sun protein VC0045 fmt NP_229704 VcCD00017440 FLH174621.01F DQ772809 methionyl-tRNA formyltransferase VC0046 def-1 NP_229705 VcCD00017425 FLH174560.01F DQ772810 polypeptide deformylase VC0047 NP_229706 VcCD00060971 FLH199227.01F DQ899321 conserved hypothetical protein VC0048 smf NP_229707 VcCD00061101 FLH234736.01F DQ899322 smf protein VC0049 smg NP_229708 VcCD00025838 FLH218733.01F DQ772811 smg protein VC0050 NP_229709 VcCD00025841 FLH218741.01F DQ772812 DNA topoisomerase I-related protein VC0051 purK NP_229710 VcCD00025581 FLH199225.01F DQ772813 phosphoribosylaminoimidazole carboxylase, ATPase subunit VC0052 purE NP_229711 VcCD00061059 FLH234628.01F DQ899323 phosphoribosylaminoimidazole carboxylase, catalytic subunit VC0053 NP_229712 VcCD00061063 FLH234638.01F DQ899324 hypothetical protein VC0054 NP_229713 VcCD00019136 FLH199252.01F DQ772814 Sua5-YciO-YrdC family protein VC0055 hemF NP_229714 VcCD00025578 FLH199202.01F DQ772815 coproporphyrinogen III oxidase, aerobic VC0056 aroE NP_229715 VcCD00019118 FLH199194.01F DQ772816 shikimate 5-dehydrogenase VC0057 NP_229716 VcCD00025826 FLH218701.01F DQ772817 conserved hypothetical protein VC0058 NP_229717 VcCD00061065 FLH234644.01F DQ899325 carbonic anhydrase, family 3 VC0060 crcB NP_229719 VcCD00019124 FLH199220.01F DQ772818 crcB protein VC0061 thiC NP_229720 VcCD00019137 FLH199255.01F DQ772819 thiamin biosynthesis protein ThiC VC0062 thiE NP_229721 VcCD00019126 FLH199234.01F DQ772820 thiamin-phosphate pyrophosphorylase VC0063 thiF NP_229722 VcCD00025576 FLH199192.01F DQ772821 thiF protein VC0064 thiS NP_229723 VcCD00025822 FLH218691.01F DQ772822 thiS protein VC0065 thiG NP_229724 VcCD00061091 FLH234708.01F DQ899326 thiG protein VC0066 thiH NP_229725 VcCD00019123 FLH199219.01F DQ772823 thiH protein VC0067 NP_229726 VcCD00061124 FLH234795.01F DQ899327 aminopeptidase P VC0068 NP_229727 VcCD00019120 FLH199211.01F DQ772824 transcriptional regulator, LysR family VC0069 NP_229728 VcCD00025835 FLH218727.01F DQ772825 multidrug resistance protein, putative VC0070 NP_229729 VcCD00019064 FLH199107.01F DQ772826 hypothetical protein VC0071 asnC NP_229730 VcCD00019085 FLH199133.01F DQ772827 transcriptional regulator AsnC VC0072 NP_229731 VcCD00061275 FLH236883.01F DQ899328 sensory box-GGDEF family protein VC0073 NP_229732 VcCD00019070 FLH199114.01F DQ772828 conserved hypothetical protein VC0074 NP_229733 VcCD00019078 FLH199123.01F DQ772829 hypothetical protein VC0075 madN NP_229734 VcCD00019072 FLH199116.01F DQ772830 MadN protein VC0076 uspA NP_229735 VcCD00019083 FLH199131.01F DQ772831 universal stress protein A VC0077 NP_229736 VcCD00019038 FLH199074.01F DQ772832 hypothetical protein VC0078 ftn NP_229737 VcCD00019098 FLH199149.01F DQ772833 ferritin VC0079 NP_229738 VcCD00019066 FLH199109.01F DQ772834 conserved hypothetical protein VC0080 NP_229739 VcCD00019084 FLH199132.01F DQ772835 conserved hypothetical protein VC0081 NP_229740 VcCD00019074 FLH199118.01F DQ772836 conserved hypothetical protein VC0082 NP_229741 VcCD00019095 FLH199146.01F DQ772837 conserved hypothetical protein VC0083 ubiE NP_229742 VcCD00019056 FLH199098.01F DQ772838 ubiquinone-menaquinone biosynthesis methlytransferase UbiE VC0084 NP_229743 VcCD00019109 FLH199163.01F DQ772839 conserved hypothetical protein VC0085 NP_229744 VcCD00017414 FLH174511.01F DQ772840 ubiquinone biosynthesis protein AarF, putative VC0086 tatA-1 NP_229745 VcCD00019055 FLH199097.01F DQ772841 tatA protein VC0087 NP_229746 VcCD00061117 FLH234778.01F DQ899329 conserved hypothetical protein VC0088 NP_229747 VcCD00019050 FLH199092.01F DQ772842 conserved hypothetical protein VC0089 yhjA NP_229748 VcCD00061097 FLH234727.01F DQ899330 cytochrome c551 peroxidase VC0090 dinF NP_229749 VcCD00025645 FLH214558.01F DQ772843 DNA-damage-inducible protein F VC0091 NP_229750 VcCD00019065 FLH199108.01F DQ772844 O-methyltransferase-related protein VC0092 lexA NP_229751 VcCD00019039 FLH199075.01F DQ772845 LexA repressor VC0093 plsB NP_229752 VcCD00020057 FLH200645.01F DQ772846 glycerol-3-phosphate acyltransferase VC0094 ubiA NP_229753 VcCD00019061 FLH199104.01F DQ772847 4-hydroxybenzoate octaprenyltransferase VC0095 ubiC NP_229754 VcCD00025647 FLH214567.01F DQ772848 chorismate--pyruvate lyase VC0096 NP_229755 VcCD00060989 FLH234246.01F DQ899331 hypothetical protein VC0097 NP_229756 VcCD00019080 FLH199127.01F DQ772849 flagellar protein FliL, putative VC0098 NP_229757 VcCD00019111 FLH199166.01F DQ772850 methyl-accepting chemotaxis protein VC0099 glpG NP_229758 VcCD00019059 FLH199102.01F DQ772851 glpG protein VC0100 glpE NP_229759 VcCD00017732 FLH175972.01F DQ772852 glpE protein VC0101 NP_229760 VcCD00017728 FLH175948.01F DQ772853 hypothetical protein VC0102 NP_229761 VcCD00017718 FLH175892.01F DQ772854 hypothetical protein VC0103 NP_229762 VcCD00017711 FLH175848.01F DQ772855 conserved hypothetical protein VC0104 NP_229763 VcCD00025502 FLH175862.01F DQ772856 hypothetical protein VC0105 hemB NP_229764 VcCD00025461 FLH174670.01F DQ772857 delta-aminolevulinic acid dehydratase VC0106 NP_229765 VcCD00017744 FLH176016.01F DQ772858 conserved hypothetical protein VC0107 NP_229766 VcCD00025504 FLH175871.01F DQ772859 hypothetical protein VC0108 polI NP_229767 VcCD00061284 FLH236919.01F DQ899332 DNA polymerase I VC0109 NP_229768 VcCD00017707 FLH175828.01F DQ772860 hypothetical protein VC0110 NP_229769 VcCD00017712 FLH175852.01F DQ772861 hypothetical protein VC0111 NP_229770 VcCD00017765 FLH176109.01F DQ772862 conserved hypothetical protein VC0112 cycA NP_229771 VcCD00017770 FLH176131.01F DQ772863 cytochrome c4 VC0113 NP_229772 VcCD00017769 FLH176125.01F DQ772864 methyltransferase-related protein VC0114 NP_229773 VcCD00017755 FLH176071.01F
Recommended publications
  • DNA REPLICATION Objectives: 1

    DNA REPLICATION Objectives: 1

    Lecture 1 DNA REPLICATION Objectives: 1. To understand the replication process and where it occurs in the cell cycle. 2. To describe the Replication Fork, Okazaki fragments and the enzymes involved in the unwinding process and replication. 3. To understand how DNA polymerase initiate the synthesis of new strands. 4. To define Telomeres and Telomerase and their clinical significance. Gene expression also called protein expression or often simply expression: is the process by which a gene's DNA sequence is converted into the structures and functions of a cell. The amount of protein that a cell expresses depends on: 1. the tissue, 2. the developmental stage of the organism 3. and the metabolic or physiologic state of the cell. DNA replication or DNA synthesis is the process of copying a double-stranded DNA strand, prior to cell division. The two resulting double strands are identical (if the replication went well), and each of them consists of one original and one newly synthesized strand. This is called semi conservative replication. 1 Prof. Dr. H.D.El-Yassin 2013 Lecture 1 The process of replication consists of three steps, initiation, replication and termination. 1. Prokaryotic replication Basic Requirement for DNA Synthesis 1. Substrates: the four deoxy nucleosides triphosphates are needed as substrates for DNA synthesis. Cleavage of the high-energy phosphate bond between the α and β phosphates provides the energy for the addition of the nucleotide. 2. Template: DNA replication cannot occur without a template. A template is required to direct the addition of the appropriate complementary deoxynucleotide to the newly synthesized DNA strand.

  • DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli

    DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Kath, James Evon. 2016. DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26718716 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA ! ! ! ! ! ! ! DNA!polymerase!exchange!and!lesion!bypass!in!Escherichia)coli! ! A!dissertation!presented! by! James!Evon!Kath! to! The!Committee!on!Higher!Degrees!in!Biophysics! ! in!partial!fulfillment!of!the!requirements! for!the!degree!of! Doctor!of!Philosophy! in!the!subject!of! Biophysics! ! Harvard!University! Cambridge,!Massachusetts! October!2015! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ©!2015!L!James!E.!Kath.!Some!Rights!Reserved.! ! This!work!is!licensed!under!the!Creative!Commons!Attribution!3.0!United!States!License.!To! view!a!copy!of!this!license,!visit:!http://creativecommons.org/licenses/By/3.0/us! ! ! Dissertation!Advisor:!Professor!Joseph!J.!Loparo! ! ! !!!!!!!!James!Evon!Kath! ! DNA$polymerase$exchange$and$lesion$bypass$in$Escherichia)coli$ $ Abstract$ ! Translesion! synthesis! (TLS)! alleviates!
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications

    Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications

    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0089535 A1 Yamashiro Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2013/0089535 A1 Yamashiro Et Al

    US 2013 0089535A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0089535 A1 Yamashiro et al. (43) Pub. Date: Apr. 11, 2013 (54) AGENT FOR REDUCING ACETALDEHYDE Publication Classification NORAL CAVITY (51) Int. Cl. (75) Inventors: Kan Yamashiro, Kakamigahara-shi (JP); A68/66 (2006.01) Takahumi Koyama, Kakamigahara-shi A638/51 (2006.01) (JP) A61O 11/00 (2006.01) A638/44 (2006.01) Assignee: AMANOENZYME INC., Nagoya-shi (52) U.S. Cl. (73) CPC. A61K 8/66 (2013.01); A61K 38/44 (2013.01); (JP) A61 K38/51 (2013.01); A61O II/00 (2013.01) (21) Appl. No.: 13/703,451 USPC .......... 424/94.4; 424/94.5; 435/191: 435/232 (22) PCT Fled: Jun. 7, 2011 (57) ABSTRACT Disclosed herein is a novel enzymatic agent effective in (86) PCT NO.: PCT/UP2011/062991 reducing acetaldehyde in the oral cavity. It has been found S371 (c)(1), that an aldehyde dehydrogenase derived from a microorgan (2), (4) Date: Dec. 11, 2012 ism belonging to the genus Saccharomyces and a threonine aldolase derived from Escherichia coli are effective in reduc (30) Foreign Application Priority Data ing low concentrations of acetaldehyde. Therefore, an agent for reducing acetaldehyde in the oral cavity is provided, Jun. 19, 2010 (JP) ................................. 2010-140O26 which contains these enzymes as active ingredients. Patent Application Publication Apr. 11, 2013 Sheet 1 of 2 US 2013/0089535 A1 FIG 1) 10.5 1 0 9.9.5 8. 5 CONTROL TA AD (BSA) ENZYME Patent Application Publication Apr. 11, 2013 Sheet 2 of 2 US 2013/0089535 A1 FIG 2) 110 the CONTROL (BSA) 100 354.
  • Enzymatic Encoding Methods for Efficient Synthesis Of

    Enzymatic Encoding Methods for Efficient Synthesis Of

    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
  • Restriction Endonucleases

    Restriction Endonucleases

    Molecular Biology Problem Solver: A Laboratory Guide. Edited by Alan S. Gerstein Copyright © 2001 by Wiley-Liss, Inc. ISBNs: 0-471-37972-7 (Paper); 0-471-22390-5 (Electronic) 9 Restriction Endonucleases Derek Robinson, Paul R. Walsh, and Joseph A. Bonventre Background Information . 226 Which Restriction Enzymes Are Commercially Available? . 226 Why Are Some Enzymes More Expensive Than Others? . 227 What Can You Do to Reduce the Cost of Working with Restriction Enzymes? . 228 If You Could Select among Several Restriction Enzymes for Your Application, What Criteria Should You Consider to Make the Most Appropriate Choice? . 229 What Are the General Properties of Restriction Endonucleases? . 232 What Insight Is Provided by a Restriction Enzyme’s Quality Control Data? . 233 How Stable Are Restriction Enzymes? . 236 How Stable Are Diluted Restriction Enzymes? . 236 Simple Digests . 236 How Should You Set up a Simple Restriction Digest? . 236 Is It Wise to Modify the Suggested Reaction Conditions? . 237 Complex Restriction Digestions . 239 How Can a Substrate Affect the Restriction Digest? . 239 Should You Alter the Reaction Volume and DNA Concentration? . 241 Double Digests: Simultaneous or Sequential? . 242 225 Genomic Digests . 244 When Preparing Genomic DNA for Southern Blotting, How Can You Determine If Complete Digestion Has Been Obtained? . 244 What Are Your Options If You Must Create Additional Rare or Unique Restriction Sites? . 247 Troubleshooting . 255 What Can Cause a Simple Restriction Digest to Fail? . 255 The Volume of Enzyme in the Vial Appears Very Low. Did Leakage Occur during Shipment? . 259 The Enzyme Shipment Sat on the Shipping Dock for Two Days.
  • Molecular Markers of Serine Protease Evolution

    Molecular Markers of Serine Protease Evolution

    The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages.
  • Polymerase Ribozyme with Promoter Recognition

    Polymerase Ribozyme with Promoter Recognition

    In vitro Evolution of a Processive Clamping RNA Polymerase Ribozyme with Promoter Recognition by Razvan Cojocaru BSc, Simon Fraser University, 2014 Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Department of Molecular Biology and Biochemistry Faculty of Science © Razvan Cojocaru 2021 SIMON FRASER UNIVERSITY Summer 2021 Copyright in this work is held by the author. Please ensure that any reproduction or re-use is done in accordance with the relevant national copyright legislation. Declaration of Committee Name: Razvan Cojocaru Degree: Doctor of Philosophy Title: In vitro Evolution of a Processive Clamping RNA Polymerase Ribozyme with Promoter Recognition Committee: Chair: Lisa Craig Professor, Molecular Biology and Biochemistry Peter Unrau Supervisor Professor, Molecular Biology and Biochemistry Dipankar Sen Committee Member Professor, Molecular Biology and Biochemistry Michel Leroux Committee Member Professor, Molecular Biology and Biochemistry Mani Larijani Internal Examiner Associate Professor, Molecular Biology and Biochemistry Gerald Joyce External Examiner Professor, Jack H. Skirball Center for Chemical Biology and Proteomics Salk Institute for Biological Studies Date Defended/Approved: August 12, 2021 ii Abstract The RNA World hypothesis proposes that the early evolution of life began with RNAs that can serve both as carriers of genetic information and as catalysts. Later in evolution, these functions were gradually replaced by DNA and enzymatic proteins in cellular biology. I start by reviewing the naturally occurring catalytic RNAs, ribozymes, as they play many important roles in biology today. These ribozymes are central to protein synthesis and the regulation of gene expression, creating a landscape that strongly supports an early RNA World.
  • Health Effects Support Document for Perfluorooctanoic Acid (PFOA)

    Health Effects Support Document for Perfluorooctanoic Acid (PFOA)

    United States Office of Water EPA 822-R-16-003 Environmental Protection Mail Code 4304T May 2016 Agency Health Effects Support Document for Perfluorooctanoic Acid (PFOA) Perfluorooctanoic Acid – May 2016 i Health Effects Support Document for Perfluorooctanoic Acid (PFOA) U.S. Environmental Protection Agency Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460 EPA Document Number: 822-R-16-003 May 2016 Perfluorooctanoic Acid – May 2016 ii BACKGROUND The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of the U.S. Environmental Protection Agency (EPA) to periodically publish a list of unregulated chemical contaminants known or anticipated to occur in public water systems and that may require regulation under SDWA. The SDWA also requires the Agency to make regulatory determinations on at least five contaminants on the Contaminant Candidate List (CCL) every 5 years. For each contaminant on the CCL, before EPA makes a regulatory determination, the Agency needs to obtain sufficient data to conduct analyses on the extent to which the contaminant occurs and the risk it poses to populations via drinking water. Ultimately, this information will assist the Agency in determining the most appropriate course of action in relation to the contaminant (e.g., developing a regulation to control it in drinking water, developing guidance, or deciding not to regulate it). The PFOA health assessment was initiated by the Office of Water, Office of Science and Technology in 2009. The draft Health Effects Support Document for Perfluoroctanoic Acid (PFOA) was completed in 2013 and released for public comment in February 2014.
  • Serine Proteases with Altered Sensitivity to Activity-Modulating

    Serine Proteases with Altered Sensitivity to Activity-Modulating

    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
  • SUPPLEMENTARY INFORMATION in Silico Signature Prediction

    SUPPLEMENTARY INFORMATION in Silico Signature Prediction

    SUPPLEMENTARY INFORMATION In Silico Signature Prediction Modeling in Cytolethal Distending Toxin-Producing Escherichia coli Strains Maryam Javadi, Mana Oloomi*, Saeid Bouzari Department of Molecular Biology, Pasteur Institute of Iran, Tehran 13164, Iran http://www.genominfo.org/src/sm/gni-15-69-s001.pdf Supplementary Table 6. Aalphabetic abbreviation and description of putative conserved domains Alphabetic Abbreviation Description 17 Large terminase protein 2_A_01_02 Multidrug resistance protein 2A0115 Benzoate transport; [Transport and binding proteins, Carbohydrates, organic alcohols] 52 DNA topisomerase II medium subunit; Provisional AAA_13 AAA domain; This family of domains contain a P-loop motif AAA_15 AAA ATPase domain; This family of domains contain a P-loop motif AAA_21 AAA domain AAA_23 AAA domain ABC_RecF ATP-binding cassette domain of RecF; RecF is a recombinational DNA repair ATPase ABC_SMC_barmotin ATP-binding cassette domain of barmotin, a member of the SMC protein family AcCoA-C-Actrans Acetyl-CoA acetyltransferases AHBA_syn 3-Amino-5-hydroxybenzoic acid synthase family (AHBA_syn) AidA Type V secretory pathway, adhesin AidA [Cell envelope biogenesis] Ail_Lom Enterobacterial Ail/Lom protein; This family consists of several bacterial and phage Ail_Lom proteins AIP3 Actin interacting protein 3; Aip3p/Bud6p is a regulator of cell and cytoskeletal polarity Aldose_epim_Ec_YphB Aldose 1-epimerase, similar to Escherichia coli YphB AlpA Predicted transcriptional regulator [Transcription] AntA AntA/AntB antirepressor AraC AraC-type
  • Supplementary File 2A Revised

    Supplementary File 2A Revised

    Supplementary file 2A. Differentially expressed genes in aldosteronomas compared to all other samples, ranked according to statistical significance. Missing values were not allowed in aldosteronomas, but to a maximum of five in the other samples. Acc UGCluster Name Symbol log Fold Change P - Value Adj. P-Value B R99527 Hs.8162 Hypothetical protein MGC39372 MGC39372 2,17 6,3E-09 5,1E-05 10,2 AA398335 Hs.10414 Kelch domain containing 8A KLHDC8A 2,26 1,2E-08 5,1E-05 9,56 AA441933 Hs.519075 Leiomodin 1 (smooth muscle) LMOD1 2,33 1,3E-08 5,1E-05 9,54 AA630120 Hs.78781 Vascular endothelial growth factor B VEGFB 1,24 1,1E-07 2,9E-04 7,59 R07846 Data not found 3,71 1,2E-07 2,9E-04 7,49 W92795 Hs.434386 Hypothetical protein LOC201229 LOC201229 1,55 2,0E-07 4,0E-04 7,03 AA454564 Hs.323396 Family with sequence similarity 54, member B FAM54B 1,25 3,0E-07 5,2E-04 6,65 AA775249 Hs.513633 G protein-coupled receptor 56 GPR56 -1,63 4,3E-07 6,4E-04 6,33 AA012822 Hs.713814 Oxysterol bining protein OSBP 1,35 5,3E-07 7,1E-04 6,14 R45592 Hs.655271 Regulating synaptic membrane exocytosis 2 RIMS2 2,51 5,9E-07 7,1E-04 6,04 AA282936 Hs.240 M-phase phosphoprotein 1 MPHOSPH -1,40 8,1E-07 8,9E-04 5,74 N34945 Hs.234898 Acetyl-Coenzyme A carboxylase beta ACACB 0,87 9,7E-07 9,8E-04 5,58 R07322 Hs.464137 Acyl-Coenzyme A oxidase 1, palmitoyl ACOX1 0,82 1,3E-06 1,2E-03 5,35 R77144 Hs.488835 Transmembrane protein 120A TMEM120A 1,55 1,7E-06 1,4E-03 5,07 H68542 Hs.420009 Transcribed locus 1,07 1,7E-06 1,4E-03 5,06 AA410184 Hs.696454 PBX/knotted 1 homeobox 2 PKNOX2 1,78 2,0E-06